GRFS
GRFS clinical trials: Grifols SA
Every trial on ClinicalTrials.gov where Grifols SA is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 90
- Trials linked
- 52
- As lead sponsor
- 38
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
GRFS on the catalyst calendar · GRFS registry changes
- Primary completion Aug 2029Sponsor estimatePhase 3NCT05645107A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections...Grifols Therapeutics LLC · HypogammaglobulinemiaRecruitingGRFSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2027Sponsor estimatePhase 3NCT07540221A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating...Grifols Therapeutics LLC · CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)RecruitingGRFSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2027Sponsor estimatePhase 3NCT07555483A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With...Grifols Therapeutics LLC · Alpha 1 Antitrypsin DeficiencyRecruitingGRFSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 31, 2028Sponsor estimatePhase 3NCT07582432A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency...Grifols Biologicals, LLC · Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin LymphomaRecruitingGRFSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 7, 2026ActualPhase 3NCT01983241Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to...Grifols Therapeutics LLC · Pulmonary Emphysema in Alpha-1 PI DeficiencyCompletedGRFSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 1, 2025ActualPhase 1/Phase 2NCT04722887A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human)...Grifols Therapeutics LLC · Alpha1-Antitrypsin DeficiencyCompletedGRFSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 6, 2012ActualPhase 4NCT00555555Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand PatientsGrifols Biologicals, LLC · Von Willebrand DiseaseTerminatedGRFSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2028Sponsor estimatePhase 3NCT02796937Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin DeficiencyGrifols Therapeutics LLC · Pulmonary Emphysema in Alpha-1 Antitrypsin DeficiencyEnrolling by invitationGRFSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 10, 2024ActualPhase 4NCT02472665Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand DiseaseGrifols Therapeutics LLC · Von Willebrand DiseaseWithdrawnGRFSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 21, 2024ActualPhase 3NCT03451292Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and AscitesGrifols Therapeutics LLC · Decompensated Cirrhosis and AscitesCompletedGRFSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 11, 2018ActualPhase 4NCT00323856Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia AGrifols Biologicals, LLC · Severe Hemophilia ACompletedGRFSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 18, 2022ActualPhase 4NCT04566692A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve...Grifols Therapeutics LLC · Primary ImmunodeficiencyCompletedGRFSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 28, 2022ActualPhase 3NCT04561115A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG)...Grifols Therapeutics LLC · Primary ImmunodeficiencyCompletedGRFSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 13, 2021ActualPhase 2NCT04547140Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus...Grifols Therapeutics LLC · COVID-19TerminatedGRFSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 10, 2021ActualPhase 3NCT04847141A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory OutpatientsGrifols Therapeutics LLC · COVID-19TerminatedGRFSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 25, 2021ActualPhase 2NCT04480424Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus...Grifols Therapeutics LLC · COVID-19CompletedGRFSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 16, 2021ActualPhase 1/Phase 2NCT02870348Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)Grifols Therapeutics LLC · Alpha1-Antitrypsin DeficiencyCompletedGRFSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 11, 2019ActualPhase 1/Phase 2NCT02281500Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital AfibrinogenemiaGrifols Therapeutics LLC · Congenital AfibrinogenemiaCompletedGRFSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 18, 2020ActualPhase 2NCT03095287Alphanate in Immune Tolerance Induction TherapyGrifols Therapeutics LLC · Hemophilia A, CongenitalTerminatedGRFSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 15, 2017ActualPhase 1/Phase 2NCT02870309Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With...Grifols Therapeutics LLC · Alpha1-Antitrypsin DeficiencyCompletedGRFSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 15, 2019ActualPhase 2NCT02872142Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral SclerosisGrifols Therapeutics LLC · Amyotrophic Lateral SclerosisCompletedGRFSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 15, 2019ActualPhase 3NCT02806986Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary ImmunodeficiencyGrifols Therapeutics LLC · Primary ImmunodeficiencyCompletedGRFSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2018ActualPhase 3NCT02413580A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis ExacerbationsGrifols Therapeutics LLC · Myasthenia Gravis ExacerbationsCompletedGRFSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2020Sponsor estimatePhase 3NCT03814798Study Evaluating IGSC 20% Flexible Dosing in Treatment-Experienced and Treatment-Naive Subjects With Primary ImmunodeficiencyGrifols Therapeutics LLC · Primary ImmunodeficiencyWithdrawnGRFSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2019ActualPhase 2NCT02473965Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia GravisGrifols Therapeutics LLC · Myasthenia GravisCompletedGRFSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 65 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner